drugset / Trial / NCT00606489

Efficacy and Safety Study of Caldolor (Intravenous Ibuprofen) in Hospitalized Adult and Pediatric Burn Patients

NCT00606489

Phase 3 Completed 61 enrolled Cumberland Pharmaceuticals
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The primary objective of this study of Caldolor administered to hospitalized adult and pediatric burn patients is to determine the efficacy of Caldolor on reducing fever when compared to placebo when administered every 6 hours for at least 24 hours.

Timeline

Start
2007-11
Primary completion
2009-05
Completion
2009-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Ibuprofen Small molecule 10 mg/kg Intravenous
Subject Ibuprofen Small molecule 800 mg Intravenous

Indications

No indication recorded.